Tolerability and Clinical Outcomes With Anesthesia Dose Reduction During Electroconvulsive Therapy
Authors' conclusion
In this retrospective cohort study, reduction of anesthesia agents was associated with reduced BVM use, with similar clinical outcomes and tolerability other than increased rates of insufficient initial sedation dosage and PIA
Study context
- Population
- Patients receiving an index course of electroconvulsive therapy (ECT) for any indication with methohexital and succinylcholine, Centre for Addiction and Mental Health, Toronto, 2017–2023included in the analysis
- Participants
- 616 patients
- Exposure
- Pre-COVID-19 vs COVID-19
- Pre-COVID-19n = 362reference
- COVID-19n = 254
- Outcome
- BVM use and complication rates (aspiration, bradycardia, insufficient initial sedation dosage, postictal agitation [PIA], residual weakness, prolonged seizures)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
BVM use and complications
COVID-19
13.8%
35 of 254
COVID-19 vs Pre-COVID-19Odds ratio (95% CI)
Insufficient initial sedation dosage
2.16(1.09–4.38)
PIA
2.81(1.76–4.56)
Observational data: associations, not effects.
Secondary outcomes
Response
P = 0.38
Methohexital dosage
P = 0.007
Succinylcholine dosage
P < 0.001
Safety
Cognitive impairment · secondary outcome
P = 0.66
Original publication
Tolerability and Clinical Outcomes With Anesthesia Dose Reduction During Electroconvulsive Therapy. JAMA Netw Open. Published 3 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →